pharmaphorum September 19, 2024
Upstream Bio has become the latest biotech to chance its arm with a public listing in the US, hoping to raise funds for inflammatory respiratory disease therapy verekitug.
The Waltham, Massachusetts-based company has advanced its TSLP inhibitor verekitug into a pair of phase 2 trials in severe asthma and chronic rhinosinusitis with nasal polyps (CRSwNP) and is also planning a mid-stage trial in chronic obstructive pulmonary disease (COPD).
It is joining the initial public offering (IPO) queue amid a flurry of IPO activity in the sector, with three biotechs listing on the Nasdaq last week – Bicara Therapeutics, Zenas BioPharma, and MBX Biosciences – while BioAge is expected to follow suit in the coming weeks.
There is a placeholder of...
Today's Sponsors
Today's Sponsor